{"entity":{"id":"qi-changsong","kind":"person","name":"Changsong Qi","aka":[],"tldr":"First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.","summary":"Changsong Qi is Associate Professor of Gastrointestinal Oncology at Peking University Cancer Hospital in Beijing. He was first author of the CT041 trials, which showed that a CAR-T cell therapy directed at Claudin 18.2, now named satricabtagene autoleucel, can shrink gastric and pancreatic tumours. Working with Lin Shen, he led the clinical conduct of the phase 1 and phase 2 studies, and his publications include the interim results of Claudin 18.2-specific CAR T cells in gastrointestinal cancers. He continues to work on immunotherapy and early-phase trials for gastric cancer.","asOf":"2026-09-08","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qi%20C%5BAuthor%5D%20claudin18.2%20CAR%20T"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2"],"drugs":["satricabtagene-autoleucel"],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of GI Oncology, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Gastric cancer","CAR-T","Claudin 18.2","Early-phase trials"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qi%20C%5BAuthor%5D%20claudin18.2%20CAR%20T"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"}]},"route":"/people/qi-changsong/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"drug":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/"}],"institution":[{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"}],"trial":[{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/"}],"paper":[{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/"}]}}